SV

Street Verdict

Analyst Scorecard

NEULANDLAB · NSE

Neuland Laboratories Limited

₹22,840

+0.77% (+₹175)

Prev. close

₹22,665

Volume

75,518

Delivery %

59.6%

As of

18 Sept 2026

Price history

Bullish

JM Financial Analysis · JM Financial Institutional Securities · 06 Aug 2026

“JM Financial holds the highest price target for Neuland Laboratories at ₹25,819, implying a significant upside potential from current levels. This bullish stance is likely driven by the company's strong Q1 results, which exceeded analyst expectations with substantial year-on-year growth in revenue, EBITDA, and net profit, despite sequential declines attributed to the lumpy nature of the CDMO business.”

Published mid-session at 09:27 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.

PENDINGCall pageClear
₹22,840+₹1,297 (+6.02%) · CALL
06 Aug 2026 → 18 Sept 2026
₹23,995Entry ₹21,54306 Aug18 Aug28 Aug08 Sept18 SeptCall published 09:27
JM Financial Analysis's call · 06 Aug 2026

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in window

Commentary

none in window

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
“JM Financial holds the highest price target for Neuland Laboratories at ₹25,819, implying a significant upside potential…”JM Financial AnalysisJM Financial Institutional SecuritiesNeuland LaboratoriesPENDING
“JM Financial holds the highest price target for Neuland Laboratories at ₹25,819, implying a significant upside potential from current levels. This bullish stance is likely driven by the company's strong Q1 results, which exceeded analyst expectations with substantial year-on-year growth in revenue, EBITDA, and net profit, despite sequential declines attributed to the lumpy nature of the CDMO business.”
Rating & targetTrack opinion →

This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded.

Read the original article

Fundamentals

About Neuland Laboratories Limited

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Davuluri Saharsh Rao

Headquarters

Hyderabad

Employees

2,183

Key stats

Market cap

₹29,303.47 Cr

P/E ratio (TTM)

58.8

Dividend yield

0.15%

EPS (TTM)

₹388.28

Beta (1Y · daily vs NIFTY 50)

0.95

Beta (5Y · monthly vs NIFTY 50)

1.34

Shares float

73.56 L

EPS · quarter ended Jun 2026

₹115.10

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹-20%0%20%40%FY21FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 2.6% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

0100200300₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

010203040₹-50%0%50%100%18 Feb 2010 Nov 2029 Jun 2114 Jul 2211 Jul 2312 Jul 2418 Jul 2524 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.25×0.5×0.75×1×FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-200 Cr0 Cr200 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹936.91 Cr₹951.08 Cr₹1,191.20 Cr₹1,558.58 Cr₹1,476.84 Cr₹2,022.99 Cr
EBITDA₹162.91 Cr₹144.70 Cr₹281.59 Cr₹475.13 Cr₹420.17 Cr₹604.66 Cr
₹80.63 Cr₹63.82 Cr₹163.52 Cr₹300.08 Cr₹260.11 Cr₹364.00 Cr
Diluted EPS₹62.85₹49.74₹127.45₹233.89₹202.74₹283.71

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
—₹1,383.49 Cr₹1,579.76 Cr₹1,832.56 Cr₹2,179.88 Cr₹2,930.14 Cr
—₹240.53 Cr₹128.45 Cr₹95.39 Cr₹157.14 Cr₹301.27 Cr
Stockholders' equity—₹840.50 Cr₹994.10 Cr₹1,282.70 Cr₹1,524.81 Cr₹1,874.47 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹189.36 Cr₹58.58 Cr₹237.21 Cr₹261.18 Cr₹317.38 Cr₹346.68 Cr
Investing cash flow₹-84.42 Cr₹-93.71 Cr₹-61.50 Cr₹-149.69 Cr₹-298.16 Cr₹-423.73 Cr
₹-113.66 Cr₹37.72 Cr₹-135.80 Cr₹-69.28 Cr₹24.96 Cr₹20.98 Cr
Capital expenditure₹-105.40 Cr₹-96.89 Cr₹-66.13 Cr₹-143.67 Cr₹-206.46 Cr₹-397.13 Cr
End cash position—₹5.09 Cr₹45.42 Cr₹87.58 Cr₹131.93 Cr₹76.67 Cr

Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Sep 22(5Q)Dec 22–Mar 23(2Q)Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24–Jun 25(3Q)Sep 25Dec 25–Mar 26(2Q)Jun 26
Promoter36.22%36.14%36.03%35.97%32.80%32.74%32.72%32.64%32.68%32.64%32.63%32.62%
Public63.78%63.86%63.97%64.03%67.20%67.26%67.28%67.36%67.32%67.36%67.37%67.38%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Neuland Laboratories Limited₹29,078.94 Cr₹22,84058.615.5119.4%0.16+34.7%+43.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 30

Concall transcripts

Show all 10

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

27 indices

Nifty MidSmall Healthcare· 3.0%Nifty Smallcap 50· 2.4%BSE SmallCap Select Index· 2.1%Nifty Smallcap250 Momentum Quality 100· 1.9%NIFTY Smallcap 100· 1.6%Nifty500 Healthcare· 1.3%BSE Healthcare· 1.2%BSE 250 SmallCap Index· 0.9%Nifty MidSmallcap400 Momentum Quality 100· 0.8%Nifty Smallcap 500· 0.6%Nifty500 Multicap India Manufacturing 50:30:20· 0.5%Nifty500 Shariah· 0.3%

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

NEULANDLAB

Neuland Laboratories (NSE: NEULANDLAB) Investor Meeting and Peptide Capacity Expansion Update

Kalkine India · 2 days ago

NEULANDLAB

Neuland Laboratories Share Price Falls 2.7% Despite Commercial Peptide Facility Milestone

Univest · 5 days ago